Compare · INSP vs WST
INSP vs WST
Side-by-side comparison of Inspire Medical Systems Inc. (INSP) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSP and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 17.4x INSP ($1.46B).
- Over the past year, INSP is down 59.7% and WST is up 70.4% - WST leads by 130.1 points.
- INSP has been more active in the news (7 items in the past 4 weeks vs 5 for WST).
- INSP has more recent analyst coverage (25 ratings vs 18 for WST).
- Company
- Inspire Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- $50.50-1.98%
- $358.18-1.11%
- Market cap
- $1.46B
- $25.31B
- 1M return
- +22.01%
- +8.72%
- 1Y return
- -59.70%
- +70.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 18
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest INSP
- Director Melenikiotou Georgia was granted 344 shares, increasing direct ownership by 4% to 8,329 units (SEC Form 4)
- Director Tansey Casey M was granted 346 shares, increasing direct ownership by 1% to 26,632 units (SEC Form 4)
- Director Ellis Gary Lee was granted 581 shares, increasing direct ownership by 5% to 11,419 units (SEC Form 4)
- Director Broader Shelley G was granted 383 shares, increasing direct ownership by 5% to 8,854 units (SEC Form 4)
- Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
- Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on July 6, 2026
- SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.
- Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Inspire Medical Systems downgraded by Evercore ISI with a new price target
- Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits